Phreesia, Inc. PHR R2KR3KPHARMA
Company Overview
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
Why Investors Should Care
Revenue has grown at a 24.7% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.18.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $467.82M (+14.0% YoY); net profit $2.31M.
- Trailing 12 Months Year-on-year growth — revenue +10.4%, earnings +200.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.73% |
| 1 Year: | 10.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 200.00% |
Stock Price Performance
| 1 Year: | -55.67% |
| 6 Months: | +33.12% |
| 3 Months: | +19.47% |
| 1 Month: | +27.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)76.08 · Overbought
P/E of 70.56 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 70.6.
- Trading 61.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 76 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHR Phreesia, Inc. R2KR3KPHARMA | 12.70 | 70.56 | $788.30M | 0.00% | -1.38% | 3.12% | 24.73% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Oct 2023 | Apr 2024 | Jul 2024 | Oct 2024 | Apr 2025 | Jul 2025 | Oct 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.87M | 24.78M | 24.76M | 26.48M | 28.31M | 30.82M | 32.84M | 32.81M | 33.40M | 35.01M | 38.46M | 48.29M | 51.01M | 55.91M | 63.35M | 67.87M | 73.10M | 83.84M | 85.83M | 91.62M | 101.22M | 102.11M | 106.80M | 115.94M | 117.25M | 120.33M | 130.94M |
| Operating Income | -1.91M | -1.25M | -3.04M | -3.30M | -4.25M | -4.14M | -2.23M | -4.67M | -4.97M | -6.31M | -6.11M | -10.65M | -23.81M | -35.74M | -50.59M | -46.34M | -39.81M | -37.90M | -36.95M | -32.05M | -19.42M | -17.22M | -13.84M | -3.29M | -1.51M | 3.74M | 6.75M |
| Net Income | -3.22M | -2.59M | -4.17M | -5.08M | -6.70M | -7.49M | -2.44M | -3.67M | -6.11M | -6.37M | -6.71M | -10.97M | -24.39M | -36.34M | -51.24M | -46.72M | -40.17M | -37.53M | -36.77M | -31.94M | -19.72M | -18.01M | -14.40M | -3.91M | 654.00K | 4.27M | 2.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.17 | -0.17 | -0.24 | -0.48 | -0.71 | -0.99 | -0.89 | -0.76 | -0.70 | -0.68 | -0.58 | -0.35 | -0.31 | -0.25 | -0.07 | 0.01 | 0.07 | 0.05 |
| R&D Expense | - | - | 3.86M | - | 4.30M | 4.69M | 4.77M | - | 5.00M | 5.53M | 5.73M | 8.05M | 11.44M | 15.27M | 20.64M | 22.54M | 22.67M | 26.47M | 27.47M | 28.54M | 28.88M | 29.54M | 29.32M | 31.83M | 29.27M | 29.45M | 28.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 79.83M | 99.89M | 124.78M | 148.68M | 213.23M | 280.91M | 345.99M | 410.48M | 467.82M |
| Operating Income | -14.55M | -9.49M | -15.30M | -25.67M | -116.82M | -176.55M | -136.48M | -58.10M | -6.61M |
| Net Income | -18.19M | -15.06M | -20.29M | -27.29M | -118.16M | -176.15M | -136.88M | -58.53M | 2.31M |
| Diluted EPS | - | - | -4.50 | -0.69 | -2.37 | -3.36 | -2.51 | -1.02 | 0.04 |
| R&D Expense | 11.38M | 14.35M | 18.62M | 22.62M | 52.27M | 91.24M | 112.35M | 117.36M | 121.48M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 59.26M | 158.76M | 326.67M | 494.48M | 370.06M | 370.33M | 388.42M | 663.79M |
| Total Equity | -130.46M | -167.68M | -210.97M | 101.86M | 263.31M | 417.28M | 287.82M | 251.45M | 264.81M | 337.21M |
| Cash & Equivalents | - | - | 1.54M | 90.31M | 218.78M | 313.81M | 176.68M | 87.52M | 84.22M | 73.83M |
| Long Term Debt | - | - | 27.92M | 19.44M | 1.63M | 360.00K | 246.00K | 3.15M | 1.94M | 2.66M |
| Total Liabilities | - | - | 63.75M | 56.89M | 63.36M | 77.20M | 82.24M | 118.88M | 123.61M | 326.58M |
| Current Liabilities | - | - | 27.93M | 35.35M | 54.99M | 68.43M | 79.04M | 110.12M | 114.02M | 183.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.14M | -2.13M | 826.00K | 2.89M | -74.71M | -90.12M | -32.38M | 32.38M | 78.81M |
| Investing Cash Flow | -11.96M | -11.02M | -12.32M | -25.09M | -65.23M | -26.20M | -39.67M | -24.09M | -161.88M |
| Financing Cash Flow | 31.29M | 4.19M | 100.27M | 150.66M | 234.97M | -20.80M | -17.11M | -11.49M | 72.85M |
| Capital Expenditure | -6.59M | -4.72M | -7.01M | -11.24M | -18.42M | -4.73M | -5.81M | -8.71M | -11.10M |
| Free Cash Flow | -17.73M | -6.85M | -6.19M | -8.35M | -93.13M | -94.86M | -38.18M | 23.67M | 67.71M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -18.2% | -9.5% | -12.3% | -17.3% | -54.8% | -62.9% | -39.4% | -14.2% | -1.4% |
| Net Margin % | -22.8% | -15.1% | -16.3% | -18.4% | -55.4% | -62.7% | -39.6% | -14.3% | 0.5% |
| ROE % | 10.8% | 7.1% | -19.9% | -10.4% | -28.3% | -61.2% | -54.4% | -22.1% | 0.7% |
| ROCE % | - | -30.3% | -12.4% | -9.4% | -27.4% | -60.7% | -52.5% | -21.2% | -1.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Pale Fire Capital SE | 14.38% | 8.92M | $96.47M |
| 2 | Blackrock Inc. | 11.31% | 7.02M | $75.88M |
| 3 | AQR Capital Management, LLC | 5.08% | 3.15M | $34.07M |
| 4 | Vanguard Portfolio Management LLC | 4.81% | 2.99M | $32.30M |
| 5 | Vanguard Capital Management LLC | 4.11% | 2.55M | $27.55M |
| 6 | Acadian Asset Management. LLC | 2.59% | 1.60M | $17.35M |
| 7 | State Street Corporation | 2.54% | 1.58M | $17.05M |
| 8 | Goldman Sachs Group Inc | 2.31% | 1.44M | $15.52M |
| 9 | Geode Capital Management, LLC | 2.11% | 1.31M | $14.18M |
| 10 | T. Rowe Price Investment Management, Inc. | 2.09% | 1.30M | $14.01M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHR
Phreesia(PHR) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMi_AJBVV95cUxNcHVZRlRDNTc4TlBKMlh0ZTVmeThoTWVEWDNBdTRnQUZhaExJb2hFYkoyYkY1S2N3RFZ5SGpGOTcxY0FCcFliOGRONnlBcVdmSnNURV9jWmQ1TmdTcUx4elRzTWhvYzJtYlI1MjlwSVMydE1ENWM3UFJFSWpEMkx1WUN2VU1uRkFmcDgzWW…
Phreesia, Inc. Estimates – NYSE:PHR - TradingView
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE9heWtXMUFHWTUwZ2U3RE1HclBsVlpuVmxLVTlaX3hYdHhWZGI0RGJhZlVaRzR5OHYySkJWWjZqNm5OMW1VVXdqYnF1WmViWWhIcWpBNmd2TDN6WGZNeHdrNGswamc1Y1l6MEdrVDAzRzJlT1FI?oc=5" target="_blank">Phreesia, I…
Should Value Investors Buy Phreesia (PHR) Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOM2RjNWUzS2YwT0lHVmlpU2JwTmVhbzBQelhsdmFxTkhoNEMyemJ3VzBRbGc0c3BRQkU1cWd5T2RzRW9FU21XYjhuUVc3ZHhDQTZHbTc2UFR0OS1DeklaMGR0eHZ5TExZTGNJbFBYT3RTbDUzQWR4Q3l6ZG92cEVNZFp0UjIxSnJnR2RIWU…
Phreesia Inc (PHR) Shares Surge 3.1% -- What GF Score of 63 Tells Investors - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRWgwMFhaMW03N3lZcUVTdVRrNFBOVEZJMnNMblB5ZmFrdEVjV1F5TjNKX3g1WHNXYW5JYnFrMzZXM3dmZGYwXy1rRXNwTk1pNFNIMjhuYUJaWkFOc29ubS1jMl81XzhvRjA0MXRpbmxRZEgtY2RVZ1duZW51cVFZZzY0VlNEOHh6UEk1U2…
PHR Mar 2027 15.000 put (PHR270319P00015000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE5Ob1BtLXl5NHMxWjhXQWJYNDZObHgtVklrX3Y4MmtYbTE5ODZzY204dzJFWjloRXlSNjFVZkFFeDJrakxYMVdPWDlwQmhHeVRPS0t1Qm1Zc0tSYUZWTVMyamI5UHQ?oc=5" target="_blank">PHR Mar 2027 15.000 put (PHR2703…
Why Phreesia Stock Got Knocked Down Today - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOcHI4OHM2cDRrd2tnS1Y5RUIwMU9MRVBCb2w5YW85OEhqX1hwaGpicEpJTXp6ckkzQ3VJc1hRRVktNm9DWFpyb0RzUG02bWZQRkI4QURmQTZ1T21oZW1YbU1QMzBtTXcxZml0LV9ZenVrWkl5bmRTU0xkNk9LcVBnT1FmVG5ONmNHYUR4NQ…
PHR — Frequently Asked Questions
What is the current share price of Phreesia, Inc. (PHR)?
As of 2026-10-23 16:27 PDT, Phreesia, Inc. (PHR) trades at $12.70 on NYSE. Its 52-week range is $8.06 to $32.55.
What is the market capitalisation of PHR?
Phreesia, Inc. (PHR) has a market capitalisation of $788.30M on NYSE.
What is the P/E ratio of PHR?
PHR trades at a trailing price-to-earnings (P/E) ratio of 70.56. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.68.
What is the return on equity (ROE) of PHR?
PHR has a return on equity (ROE) of 3.12%. Its return on capital employed (ROCE) is -1.38%.
Is PHR a good stock to buy?
This page provides a data-driven analysis of Phreesia, Inc. (PHR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.